Equities analysts expect Acorda Therapeutics Inc (NASDAQ:ACOR) to post ($0.05) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Seven analysts have made estimates for Acorda Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.34) and the highest estimate coming in at $0.32. Acorda Therapeutics posted earnings of $0.43 per share during the same quarter last year, which would suggest a negative year over year growth rate of 111.6%. The company is scheduled to report its next earnings report on Tuesday, October 30th.

According to Zacks, analysts expect that Acorda Therapeutics will report full-year earnings of $0.46 per share for the current financial year, with EPS estimates ranging from ($0.17) to $1.61. For the next financial year, analysts anticipate that the business will post earnings of ($2.45) per share, with EPS estimates ranging from ($4.35) to $0.55. Zacks’ earnings per share calculations are a mean average based on a survey of research analysts that follow Acorda Therapeutics.

Acorda Therapeutics (NASDAQ:ACOR) last released its quarterly earnings data on Thursday, August 2nd. The biopharmaceutical company reported $1.40 earnings per share for the quarter, beating analysts’ consensus estimates of $0.50 by $0.90. The business had revenue of $153.30 million during the quarter, compared to analyst estimates of $138.63 million. Acorda Therapeutics had a negative net margin of 26.87% and a positive return on equity of 8.19%. Acorda Therapeutics’s revenue was up 10.0% compared to the same quarter last year. During the same period last year, the business earned $0.29 EPS.

A number of analysts have weighed in on the stock. BidaskClub lowered shares of Acorda Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, July 26th. Stifel Nicolaus raised their price objective on shares of Acorda Therapeutics from $15.00 to $25.00 and gave the company a “hold” rating in a research note on Tuesday, August 7th. ValuEngine lowered shares of Acorda Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, July 25th. Zacks Investment Research upgraded shares of Acorda Therapeutics from a “hold” rating to a “buy” rating and set a $33.00 price objective for the company in a research note on Tuesday, July 3rd. Finally, Oppenheimer set a $21.00 price target on shares of Acorda Therapeutics and gave the stock a “hold” rating in a research note on Wednesday, July 25th. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating and six have assigned a buy rating to the company. Acorda Therapeutics has an average rating of “Hold” and an average target price of $23.54.

NASDAQ:ACOR traded up $0.35 on Friday, reaching $28.20. 229,600 shares of the stock traded hands, compared to its average volume of 595,989. The firm has a market cap of $1.28 billion, a P/E ratio of 27.12 and a beta of 1.46. The company has a debt-to-equity ratio of 0.56, a quick ratio of 3.92 and a current ratio of 4.09. Acorda Therapeutics has a 12 month low of $16.55 and a 12 month high of $36.35.

In other news, insider Burkhard Blank sold 6,250 shares of Acorda Therapeutics stock in a transaction that occurred on Wednesday, August 1st. The shares were sold at an average price of $24.69, for a total value of $154,312.50. Following the completion of the sale, the insider now directly owns 34,400 shares in the company, valued at $849,336. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Andrew A. Hindman sold 42,615 shares of Acorda Therapeutics stock in a transaction that occurred on Friday, May 25th. The stock was sold at an average price of $24.26, for a total transaction of $1,033,839.90. Following the completion of the sale, the insider now owns 4,503 shares of the company’s stock, valued at $109,242.78. The disclosure for this sale can be found here. Insiders sold 1,431,151 shares of company stock valued at $43,408,127 over the last quarter. Company insiders own 7.80% of the company’s stock.

Several hedge funds have recently made changes to their positions in ACOR. NumerixS Investment Technologies Inc grew its stake in shares of Acorda Therapeutics by 123.5% in the second quarter. NumerixS Investment Technologies Inc now owns 3,800 shares of the biopharmaceutical company’s stock worth $105,000 after acquiring an additional 2,100 shares during the period. Xact Kapitalforvaltning AB purchased a new position in shares of Acorda Therapeutics in the first quarter worth approximately $206,000. Dynamic Technology Lab Private Ltd purchased a new position in shares of Acorda Therapeutics in the second quarter worth approximately $218,000. Crossmark Global Holdings Inc. purchased a new position in shares of Acorda Therapeutics in the second quarter worth approximately $229,000. Finally, Sun Life Financial INC purchased a new position in shares of Acorda Therapeutics in the second quarter worth approximately $237,000.

Acorda Therapeutics Company Profile

Acorda Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Qutenza, a dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia.

Further Reading: Fundamental Analysis

Get a free copy of the Zacks research report on Acorda Therapeutics (ACOR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Acorda Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.